At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 9 enrolled
Drug / intervention
Rituximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Rituximab - Immunotherapy for Schizophrenia Spectrum Disorder in Adults: An Open Pilot Study
In Brief
A Phase 2 clinical trial evaluating Rituximab for Schizophrenia Spectrum and Other Psychotic Disorders and Treatment-resistant Schizophrenia. Completed, enrolled 9 participants across 1 site.
Detailed Summary
This study evaluates the addition of rituximab to 12 patients diagnosed with treatment resistant schizophrenia spectrum disorder in an open trial.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesSweden
CollaboratorsÖrebro University, Sweden
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedJun 2019
Enrollment StartAug 2019
Primary CompletionMar 2022
TodayJul 2026
First PostedJun 12, 2019
Enrollment StartAug 7, 2019
Primary CompletionMar 31, 2022
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.1 years ago
Interventions
Rituximabdrug
Infusion